| HOME >> BIOLOGY >> TECHNOLOGY |
These non GAAP measures should not be considered in isolation from, as substitutes for, or superior to financial measures prepared in accordance with US GAAP.
Interim Management Statement
This report is to be taken as fulfilling the requirements of the Interim Management Statement as required by the UK's Financial Services Authority's Disclosure and Transparency Rules.
The following are trademarks either owned or licensed by Shire plc or
companies within the Shire Group which are the subject of trademark
registrations in certain territories:
Shire Product Active ingredient
ADDERALL XR(R) (mixed salts of a single-entity amphetamine)
AMIGAL (migalastat hydrochloride) (trademark of Amicus
Therapeutics ("Amicus"))
CALCICHEW(R) range (calcium carbonate with or without vitamin D3)
CARBATROL(R) (carbamazepine - extended-release capsules)
COMBIVIR (lamivudine) (trademark of GlaxoSmithKline
("GSK"))
DAYTRANA(TM) (methylphenidate transdermal system)
DYNEPO (epoetin delta) (trademark of Sanofi-Aventis)
ELAPRASE(R) (idursulfase)
EPIVIR (lamivudine) (trademark of GSK)
EPZICOM/KIVEXA (EPZICOM) (lamivudine) (trademark of GSK)
FOSRENOL(R) (lanthanum carbonate)
GENE-ACTIVATED(R)
INTUNIV(TM) (guanfacine - extended release)
JUVISTA (human TGF beta 3) (trademark of Renovo)
LIALDA(TM) (mesalamine)
METAZYM(TM) (arylsulfatase-A)
MEZAVANT(R) (mesalazine)
PENTASA (mesalamine) (trademark of Ferring)
PLICERA (isofagomine tartrate) (trademark of Amicus)
'/>"/>
| SOURCE Shire plc Copyright©2008 PR Newswire. All rights reserved |